Bristol-Myers Hepatitis C Drug to Lose Special Status From FDA

Bristol-Myers Squibb Co. said a hepatitis C drug will lose a special designation from U.S. regulators that may have led to faster market approval.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.